This article presents a review of multiple myeloma, precursor states, and related plasma cell disorders. The clinical roles of fluorodeoxyglucose PET/computed tomography (CT) and the potential to improve the management of patients with multiple myeloma are discussed. The clinical and research data supporting the utility of PET/CT use in evaluating myeloma and other plasma cell dyscrasias continues to grow.
Keywords: Fluorodeoxyglucose; Monoclonal gammopathy; Multiple myeloma; PET; PET/CT; Plasmacytoma.
Copyright © 2015 Elsevier Inc. All rights reserved.